ロード中...
Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. At present, limited data exists with regard to the safety and efficacy of sorafenib in treating CP-B HCC patients. The present study describes the use of sorafenib in...
保存先:
出版年: | Oncol Lett |
---|---|
主要な著者: | , , , , , , , , , , |
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
D.A. Spandidos
2015
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4356395/ https://ncbi.nlm.nih.gov/pubmed/25789012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.2960 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|